JP2013529686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529686A5 JP2013529686A5 JP2013518572A JP2013518572A JP2013529686A5 JP 2013529686 A5 JP2013529686 A5 JP 2013529686A5 JP 2013518572 A JP2013518572 A JP 2013518572A JP 2013518572 A JP2013518572 A JP 2013518572A JP 2013529686 A5 JP2013529686 A5 JP 2013529686A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- kinase inhibitor
- polyethylene glycol
- weight
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 67
- 238000009472 formulation Methods 0.000 claims description 65
- 229940043355 kinase inhibitor Drugs 0.000 claims description 21
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- -1 caprylate ester Chemical class 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229940080812 glyceryl caprate Drugs 0.000 claims description 6
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 6
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 claims description 6
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35969410P | 2010-06-29 | 2010-06-29 | |
| US61/359,694 | 2010-06-29 | ||
| PCT/US2011/042162 WO2012006081A1 (en) | 2010-06-29 | 2011-06-28 | Oral formulation of kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529686A JP2013529686A (ja) | 2013-07-22 |
| JP2013529686A5 true JP2013529686A5 (https=) | 2014-08-14 |
| JP5936609B2 JP5936609B2 (ja) | 2016-06-22 |
Family
ID=45441513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518572A Expired - Fee Related JP5936609B2 (ja) | 2010-06-29 | 2011-06-28 | キナーゼインヒビターの経口製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9375402B2 (https=) |
| EP (1) | EP2588081A4 (https=) |
| JP (1) | JP5936609B2 (https=) |
| CN (1) | CN103313697B (https=) |
| AU (1) | AU2011276552B2 (https=) |
| CA (1) | CA2803004A1 (https=) |
| MX (1) | MX340819B (https=) |
| NZ (1) | NZ604583A (https=) |
| WO (1) | WO2012006081A1 (https=) |
| ZA (1) | ZA201300009B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | 選択的ｆａｋ阻害剤 |
| EP2846773A4 (en) | 2012-05-10 | 2015-12-30 | Painreform Ltd | DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656182A (en) | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
| US20040006005A1 (en) * | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0114814A (pt) * | 2000-10-11 | 2005-01-25 | Cephalon Inc | Composições compreendendo composto de modafinila e seu uso |
| AR040456A1 (es) | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
| US20080119515A1 (en) * | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| GT200500310A (es) * | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| ES2533258T3 (es) | 2005-02-18 | 2015-04-08 | Janssen Sciences Ireland Uc | Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH |
| WO2007050574A1 (en) * | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| EP2012753A2 (en) | 2006-04-28 | 2009-01-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| EP2046292B1 (en) * | 2006-07-21 | 2010-03-03 | Novartis AG | Formulations for benzimidazolyl pyridyl ethers |
| DK2134689T3 (da) * | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2009105498A1 (en) | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| MX2010014057A (es) | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| CN102648197A (zh) | 2009-08-12 | 2012-08-22 | 铂雅制药公司 | 促进细胞凋亡和抑制转移的方法 |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2011
- 2011-06-28 MX MX2012014982A patent/MX340819B/es active IP Right Grant
- 2011-06-28 AU AU2011276552A patent/AU2011276552B2/en not_active Ceased
- 2011-06-28 WO PCT/US2011/042162 patent/WO2012006081A1/en not_active Ceased
- 2011-06-28 JP JP2013518572A patent/JP5936609B2/ja not_active Expired - Fee Related
- 2011-06-28 CN CN201180042122.1A patent/CN103313697B/zh not_active Expired - Fee Related
- 2011-06-28 EP EP11804122.7A patent/EP2588081A4/en not_active Withdrawn
- 2011-06-28 NZ NZ604583A patent/NZ604583A/en not_active IP Right Cessation
- 2011-06-28 CA CA2803004A patent/CA2803004A1/en not_active Abandoned
-
2013
- 2013-01-02 ZA ZA2013/00009A patent/ZA201300009B/en unknown
- 2013-08-14 US US13/967,270 patent/US9375402B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2830033T3 (es) | Composiciones de solución sólida y uso en enfermedad cardiovascular | |
| EP3431075A1 (en) | Edaravone dosage form | |
| JP2015511638A5 (https=) | ||
| Zhang et al. | Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation | |
| TWI838700B (zh) | 口服紫杉烷組合物及方法 | |
| JP6276756B2 (ja) | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤 | |
| CN1261790A (zh) | 亲脂性化合物的自体乳化剂 | |
| EP3148645A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| JP2015516418A5 (https=) | ||
| WO2020247912A1 (en) | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof | |
| RU2013126259A (ru) | Фармацевтическая композиция таксоидов | |
| JP2013529686A5 (https=) | ||
| NZ603872A (en) | Oral dosage forms of bendamustine | |
| JP2019516726A5 (https=) | ||
| JP2022088622A (ja) | がん療法のためのメトロノミック経口ゲムシタビン | |
| JP5936609B2 (ja) | キナーゼインヒビターの経口製剤 | |
| WO2014015153A2 (en) | Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 | |
| KR101612259B1 (ko) | 고농도의 탁산을 포함하는 경구 투여용 약학 조성물 | |
| US20170165231A1 (en) | Treating ewing's sarcoma and ews-fli1 related disorders | |
| JPWO2022159872A5 (https=) |